var data={"title":"Darier disease","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Darier disease</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/darier-disease/contributors\" class=\"contributor contributor_credentials\">Daniel Hohl, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/darier-disease/contributors\" class=\"contributor contributor_credentials\">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/darier-disease/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/darier-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 24, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H7872118\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Darier disease, also known as Darier-White disease, keratosis follicularis, or dyskeratosis follicularis (MIM #124200), is a rare autosomal dominant genodermatosis characterized by a persistent eruption of red-brown, keratotic papules scattered to confluent in a seborrheic distribution, nail abnormalities, pitting of palms and soles, and mucosal changes [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/1\" class=\"abstract_t\">1</a>]. The disease usually starts around puberty and runs a chronic course with exacerbations induced by sun exposure, heat, friction, or infections.</p><p>This topic will discuss the pathogenesis, clinical features, diagnosis, and management of Darier disease. Other acantholytic skin disorders, including Hailey-Hailey disease and Grover disease, are discussed separately. (See <a href=\"topic.htm?path=hailey-hailey-disease-benign-familial-pemphigus\" class=\"medical medical_review\">&quot;Hailey-Hailey disease (benign familial pemphigus)&quot;</a> and <a href=\"topic.htm?path=grovers-disease-transient-and-persistent-acantholytic-dermatosis\" class=\"medical medical_review\">&quot;Grover's disease (transient and persistent acantholytic dermatosis)&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H7872125\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Darier disease occurs worldwide with a prevalence of 1 to 4 per 100,000 [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/2,3\" class=\"abstract_t\">2,3</a>]. The disease affects both sexes and all ethnic groups. </p><p class=\"headingAnchor\" id=\"H7872132\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mutations in the <em>ATP2A2</em> gene that encodes a <span class=\"nowrap\">sarco/endoplasmic</span> reticulum Ca<sup>2+</sup>-adenosine triphosphate (ATP)ase pump (SERCA2) lead to both acantholysis and apoptosis, accounting for the characteristic pathologic finding of acantholytic dyskeratosis in Darier disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/4\" class=\"abstract_t\">4</a>]. SERCA2 actively transports calcium ions from the cytosol into the lumen of the endoplasmic reticulum to maintain a low cytoplasmic Ca<sup>2+</sup> level. Specific mutations of SERCA2 induce defects in protein expression, ATP hydrolysis, calcium transport, and calcium binding and kinetics [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/5\" class=\"abstract_t\">5</a>]. SERCA2 mutations also have been associated with impaired synthesis, folding, or trafficking of desmosomal proteins and abnormal cytokeratin expression [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/6-8\" class=\"abstract_t\">6-8</a>]. </p><p>Despite its ubiquitous expression, the lack of compensatory SERCA3 expression in keratinocytes may explain their particular vulnerability to SERCA2 deficiency. SERCA2 haploinsufficiency has been proposed to underlie the dominant transmission pattern by affecting Ca<sup>2+</sup>-mediated maturation of cellular adhesion proteins and desmosomes in the endoplasmic reticulum through a stress response, resulting in decreased strength of intercellular adhesion [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/9\" class=\"abstract_t\">9</a>]. </p><p>This mechanism has been used to develop a potential treatment. The glucosylceramide synthase inhibitor <a href=\"topic.htm?path=miglustat-drug-information\" class=\"drug drug_general\">miglustat</a>, a pharmacologic chaperone (small-molecule agents that enter cells and interact with mutant proteins allowing their correct folding and routing within the cell) used to treat mild to moderate Gaucher disease and Niemann-Pick type-C&nbsp;disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/10\" class=\"abstract_t\">10</a>], has been found to restore mature adhesion junctions and desmosomes and increase adhesion strength in Darier keratinocytes [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/9\" class=\"abstract_t\">9</a>]. This observation further supports the hypothesis of junctional adhesion protein misfolding as a pathogenetic mechanism in Darier disease. (See <a href=\"topic.htm?path=gaucher-disease-treatment\" class=\"medical medical_review\">&quot;Gaucher disease: Treatment&quot;</a> and <a href=\"topic.htm?path=overview-of-niemann-pick-disease\" class=\"medical medical_review\">&quot;Overview of Niemann-Pick disease&quot;</a>.) </p><p>Alternatively, it has been proposed that mutant <em>ATP2A2</em> protein-insoluble aggregates that are not degraded by proteasomes induce endoplasmic reticulum stress and apoptosis, leading to acantholysis and dyskeratosis [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/11\" class=\"abstract_t\">11</a>]. However, this hypothesis is based upon in vitro studies using an immortal keratinocyte cell line with strongly overexpressed mutant SERCA2 pumps and may not apply to keratinocytes from Darier skin, which in most cases show a reduced expression of SERCA2 [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>Further pleiotropic faulty SERCA2-controlled Ca<sup>2+</sup>-dependent keratinocyte adhesion in Darier disease appears to be mediated by sphingolipid [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/14\" class=\"abstract_t\">14</a>] and protein kinase C (PKC)-alpha signaling [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/15\" class=\"abstract_t\">15</a>]. </p><p class=\"headingAnchor\" id=\"H31790782\"><span class=\"h1\">GENETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Darier disease is inherited in an autosomal dominant pattern, with complete penetrance and variable expressivity. Indeed, family history is often mistakenly dismissed due to its variable expressivity with clinical presentations too subtle to be recognized. </p><p>Haploinsufficiency (where one copy of the wild-type gene is not able to prevent disease) is thought to be the mechanism for the autosomal dominant inheritance pattern, but aggregates of mutant SERCA2 <span class=\"nowrap\">(sarco/endoplasmic</span> reticulum Ca<sup>2+</sup>-adenosine triphosphate [ATP]ase pump) were also proposed to exert a dominant negative effect. (See <a href=\"#H7872132\" class=\"local\">'Pathogenesis'</a> above.) </p><p>Over 250 familial and sporadic mutations in <em>ATP2A2</em> have been identified in patients with Darier disease, primarily missense mutations and frameshift mutations [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/16,17\" class=\"abstract_t\">16,17</a>]. The observation that family members with identical <em>ATP2A2</em> mutations may have significant differences in the clinical manifestations of the disease suggests that other genes or environmental factors affect disease expression [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/18\" class=\"abstract_t\">18</a>]. Along these lines, most studies could not identify robust genotype-phenotype correlations [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/17\" class=\"abstract_t\">17</a>]. However, the allelic acrokeratosis verruciformis of Hopf is caused by specific mutations in exon 14 encoding for the Ca<sup>2+</sup>-binding domain of SERCA2 [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/19-21\" class=\"abstract_t\">19-21</a>]. Whether other particular clinical subtypes such as acral-hemorrhagic, comedonal, or neuropsychiatric presentations are due to specific mutations is more controversial [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/17,22\" class=\"abstract_t\">17,22</a>].</p><p class=\"headingAnchor\" id=\"H49418038\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acantholysis and dyskeratosis are the main histologic features of Darier disease. Acantholysis is due to the loss of cell adhesion by desmosomes and detachment of keratin filaments from desmosomes, leading to characteristic rounding up of keratinocytes with suprabasal cleft formation. Dyskeratosis is a result of keratinocyte apoptosis and characterized by nuclear condensation and perinuclear keratin clumping.</p><p>Two types of dyskeratotic cells are present in Darier disease:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&quot;Corps ronds&quot; &ndash; Corp ronds are acantholytic, enlarged, round keratinocytes predominantly located in the stratum spinosum and stratum granulosum characterized by an irregular, eccentric, and sometimes pyknotic nucleus; a clear perinuclear halo; and encircled by a brightly eosinophilic ring of collapsed keratin bundles.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&quot;Grains&quot; &ndash; Grains are mostly located in the stratum corneum and consist of small, oval cells characterized by an intensely eosinophilic cytoplasm composed of collapsed keratin bundles and centered by elongated, shrunken, cigar-shaped nuclei.</p><p/><p>The epidermis with such acantholytic and dyskeratotic foci is thickened, contains large keratin plugs that fill the pilosebaceous follicles but are also found outside of follicles, and shows focal parakeratosis, papillomatosis, and hyperkeratosis. The underlying dermal papillae, covered by a single layer of epithelium (stratum basale), project into the clefts forming villus-like structures (<a href=\"image.htm?imageKey=DERM%2F86189\" class=\"graphic graphic_picture graphicRef86189 \">picture 1</a>). </p><p class=\"headingAnchor\" id=\"H7872139\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H49417901\"><span class=\"h2\">Skin lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In approximately 70 percent of patients, the initial lesions of Darier disease typically appear between the ages of 6 and 20 years and peak during the teenage years. The appearance is that of skin-colored or red-brown, keratotic, sometimes yellowish, crusted papules with a greasy, warty texture [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/23\" class=\"abstract_t\">23</a>]. The lesions typically involve the seborrheic areas (ie, forehead, scalp, notably the hairline, nasolabial folds, lateral aspects of the neck, presternal and interscapular areas) and may coalesce to form large, crusted, papillomatous masses (<a href=\"image.htm?imageKey=DERM%2F70000%7EDERM%2F56168%7EDERM%2F86186%7EDERM%2F86187%7EDERM%2F86188\" class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188 \">picture 2A-E</a>). </p><p>Most patients also have mild involvement of the intertriginous areas (groin, axillae, and, in women, submammary fold). In a small subset of patients, flexural disease predominates with large, warty, vegetative plaques in the axillae, groin, or perineum. Flexural lesions may be disabling because of maceration and malodor.</p><p>The hands are involved in most patients. Palmar lesions include punctate keratoses, pits, and, less frequently, hemorrhagic macules. In severe cases, palmoplantar hyperkeratosis may occur (<a href=\"image.htm?imageKey=DERM%2F86185\" class=\"graphic graphic_picture graphicRef86185 \">picture 3</a>). Many patients have warty, flat-topped papules on the dorsa of the hands and feet. These are clinically indistinguishable from acrokeratosis verruciformis, an allelic autosomal dominant clinical subtype of Darier disease, which affects preferentially the dorsa of the hands and feet. (See <a href=\"#H1908421141\" class=\"local\">'Acrokeratosis verruciformis of Hopf'</a> below.)</p><p class=\"headingAnchor\" id=\"H49417908\"><span class=\"h2\">Nail changes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Changes of the finger nails are present in most patients with Darier disease and provide an important diagnostic clue [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/24,25\" class=\"abstract_t\">24,25</a>]. White (<a href=\"image.htm?imageKey=DERM%2F113564\" class=\"graphic graphic_picture graphicRef113564 \">picture 4</a>) and red longitudinal bands (ie, linear erythronychia) (<a href=\"image.htm?imageKey=DERM%2F113565\" class=\"graphic graphic_picture graphicRef113565 \">picture 5</a>), longitudinal nail ridges and splitting, notching of the free nail border (<a href=\"image.htm?imageKey=DERM%2F113566\" class=\"graphic graphic_picture graphicRef113566 \">picture 6</a>), and wedge-shaped subungual hyperkeratosis are common. A sandwich of red and white longitudinal bands, often with a V-shaped nick at the free margin of the nail, is a pathognomonic finding (<a href=\"image.htm?imageKey=DERM%2F81865\" class=\"graphic graphic_picture graphicRef81865 \">picture 7</a>). Less commonly, these nail changes also occur on the toes. (See <a href=\"topic.htm?path=overview-of-nail-disorders#H343070\" class=\"medical medical_review\">&quot;Overview of nail disorders&quot;, section on 'Darier disease'</a>.)</p><p class=\"headingAnchor\" id=\"H49417918\"><span class=\"h2\">Mucosal lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mucosal lesions consisting of white papules with a central depression may be frequently seen in patients with Darier disease (<a href=\"image.htm?imageKey=DERM%2F86184\" class=\"graphic graphic_picture graphicRef86184 \">picture 8</a>). These cobblestone lesions are found in the oral cavity and pharynx in approximately half of the cases but may also occur in the esophagus and on the anogenital mucosa [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/26-29\" class=\"abstract_t\">26-29</a>]. At times, oral lesions may cause blockage of the salivary ducts, particularly of the parotid gland, and xerostomia [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H58289047\"><span class=\"h2\">Symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with Darier disease complain of moderate itch, while intertriginous lesions may cause pain. Particularly distressing are malodor and appearance, which often lead to social isolation. </p><p class=\"headingAnchor\" id=\"H49417925\"><span class=\"h2\">Associated neuropsychiatric abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although neuropsychiatric abnormalities such as epilepsy, mental impairment, and mood disorders have been reported in association with Darier disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/31,32\" class=\"abstract_t\">31,32</a>], it is unclear whether particular mutations in <em>ATP2A2</em> or a closely linked susceptibility gene are associated with these disorders [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/22,31,33,34\" class=\"abstract_t\">22,31,33,34</a>]. Although several studies support a pleiotropic effect of <em>ATP2A2</em> mutations on developmental delay and psychiatric morbidity in patients with Darier disease, disfigurement and social isolation associated with severe skin disease may be contributing factors [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/32,35-37\" class=\"abstract_t\">32,35-37</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H58289039\"><span class=\"h1\">CLINICAL VARIANTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical variants of Darier disease include hypertrophic, verrucous, vesicobullous (dyshidrotic), erosive, and predominantly intertriginous forms. Segmental, acral hemorrhagic, and acrokeratosis verruciformis of Hopf are other distinctive variants of the disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/17,22,38-41\" class=\"abstract_t\">17,22,38-41</a>]. </p><p class=\"headingAnchor\" id=\"H96302336\"><span class=\"h2\">Segmental variant</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Linear or segmental forms of Darier disease may result from genetic mosaicism of <em>ATP2A2 </em>[<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/42\" class=\"abstract_t\">42</a>]. Type 1 mosaicism, reflecting a postzygotic somatic mutation in <em>ATP2A2</em> early during embryogenesis, presents with one or more unilateral bands of keratotic papules following the Blaschko lines [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/43\" class=\"abstract_t\">43</a>]. Type 2 mosaicism reflects a postzygotic mutation causing loss of heterozygosity at the <em>ATP2A2</em> locus and manifests with more severely affected linear bands of lesions superimposed on generalized disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"headingAnchor\" id=\"H161132089\"><span class=\"h2\">Acral hemorrhagic variant</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acral hemorrhagic Darier disease is an uncommon variant presenting with hemorrhagic macules, papules, or blisters located on the extremities, sometimes induced by trauma [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/40,45-47\" class=\"abstract_t\">40,45-47</a>]. This variant has been reported within families, but no specific genotype-phenotype correlation has been established. </p><p class=\"headingAnchor\" id=\"H1908421141\"><span class=\"h2\">Acrokeratosis verruciformis of Hopf</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acrokeratosis verruciformis of Hopf (AKV, MIM #101900) is an autosomal dominant allelic &quot;forme fruste&quot; of Darier disease, caused in most cases by a specific <em>ATP2A2</em> missense mutation [p.(Pro602Leu)] [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/19,21,48\" class=\"abstract_t\">19,21,48</a>]. In his original report, Hopf also described nail changes and palmoplantar pits in his patients. </p><p>AKV is characterized by asymptomatic, skin-colored, flat-topped, wart-like papules on the dorsal aspects of the hands and feet and palmoplantar pits and punctate keratoses (<a href=\"image.htm?imageKey=DERM%2F86092%7EDERM%2F86093\" class=\"graphic graphic_picture graphicRef86092 graphicRef86093 \">picture 9A-B</a>). Histologically, AKV demonstrates undulating hyperkeratosis, papillomatosis, and hypergranulosis creating a &quot;church spire&quot; appearance, but acantholysis is generally absent, although the examination of serial sections from AKV lesions may show overlapping features with Darier disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/49\" class=\"abstract_t\">49</a>].</p><p>Lesions of AKV are a common finding in patients with classic Darier disease. Warty lesions on the extremities may be an early manifestation of the disease, preceding the appearance of typical keratotic papules in a seborrheic distribution, particularly after intense sun exposure [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/21,24\" class=\"abstract_t\">21,24</a>].</p><p class=\"headingAnchor\" id=\"H49418100\"><span class=\"h1\">CLINICAL COURSE AND COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the severity of Darier disease is variable, the condition generally runs a chronic course with frequent exacerbations. Exacerbating factors include heat, sweat, sun exposure, friction, or infection [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/23,50\" class=\"abstract_t\">23,50</a>]. <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a> carbonate (commonly used to treat bipolar disorder) [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/44,51\" class=\"abstract_t\">44,51</a>] or calcium channel blockers [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/52\" class=\"abstract_t\">52</a>] can provoke flares of Darier disease and should be avoided.</p><p>Bacterial, particularly staphylococcal, and fungal infections are frequent complications and can be severe or even fatal [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/53\" class=\"abstract_t\">53</a>]. The malodor of the skin lesions is a source of considerable distress for patients and may lead to social isolation.</p><p>Widespread herpes simplex virus infection (eczema herpeticum, also known as Kaposi varicelliform eruption) and smallpox virus infection may rarely occur in patients with Darier disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/54,55\" class=\"abstract_t\">54,55</a>]. In a retrospective study of 79 patients with Darier disease, herpes simplex virus was detected in lesional skin in 11 patients (14 percent) [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/56\" class=\"abstract_t\">56</a>]. Eczema herpeticum is suspected if there is a sudden eruption of vesicular and crusted lesions with skin pain and fever. However, superinfection with herpes simplex virus may present as impetiginized erosions in the absence of vesicles or pustules [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/56\" class=\"abstract_t\">56</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection#H31627071\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of herpes simplex virus type 1 infection&quot;, section on 'Eczema herpeticum'</a>.)</p><p>Ocular complications include warty, hyperkeratotic plaques with debris accumulation on the eyelid margin and chronic blepharitis (<a href=\"image.htm?imageKey=DERM%2F113572\" class=\"graphic graphic_picture graphicRef113572 \">picture 10</a>) [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/57\" class=\"abstract_t\">57</a>]. Corneal ulcerations, recurrent herpetic keratitis, and staphylococcal endophthalmitis following cataract surgery have also been reported [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/58-60\" class=\"abstract_t\">58-60</a>]. </p><p>There are a few reports of squamous cell carcinomas arising in cutaneous or mucosal sites chronically affected by Darier disease [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/61,62\" class=\"abstract_t\">61,62</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H7872153\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of Darier disease is suggested by the clinical finding of a persistent eruption of skin-colored or yellow-brown, keratotic papules involving seborrheic areas such as forehead, hairline, nasolabial folds, ears, chest, and back (<a href=\"image.htm?imageKey=DERM%2F70000%7EDERM%2F56168%7EDERM%2F86186%7EDERM%2F86187%7EDERM%2F86188\" class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188 \">picture 2A-E</a>). Nail changes, including white and red longitudinal bands, a V-shaped nick at the free nail margin, and subungual hyperkeratosis, are an important diagnostic clue (<a href=\"image.htm?imageKey=DERM%2F81865\" class=\"graphic graphic_picture graphicRef81865 \">picture 7</a>). A sandwich of red and white longitudinal bands, often with a V-shaped nick at the free margin of the nail, is a pathognomonic finding. (See <a href=\"#H7872139\" class=\"local\">'Clinical features'</a> above.)</p><p>A skin biopsy for<strong> </strong>histologic examination is needed to confirm the diagnosis. The histologic diagnosis is based upon the finding of focal suprabasal acantholysis and dyskeratosis with characteristic eosinophilic &quot;corps ronds&quot; and &quot;grains&quot; in the epidermis and stratum corneum. (See <a href=\"#H49418038\" class=\"local\">'Histopathology'</a> above.)</p><p>When bacterial or fungal superinfection is suspected, bacterial and fungal cultures of the involved sites are useful to determine appropriate antibiotic or antifungal treatment. In patients with vesicular lesions suggesting herpes virus superinfection (eczema herpeticum), a Tzanck smear <span class=\"nowrap\">and/or</span> viral culture can confirm the diagnosis. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection#H26\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of herpes simplex virus type 1 infection&quot;, section on 'Viral culture'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection#H30\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of herpes simplex virus type 1 infection&quot;, section on 'Tzanck smear'</a>.) </p><p class=\"headingAnchor\" id=\"H7872160\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of Darier disease may include severe seborrheic dermatitis, Hailey-Hailey disease, and Grover disease. However, Darier disease is readily distinguished by the clinical involvement of acral skin, nails, and oral mucosa.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Seborrheic dermatitis</strong> &ndash; The skin lesions of seborrheic dermatitis are erythematous plaques with yellowish, greasy scales involving the scalp, eyebrows, nasolabial folds, or, occasionally, flexural areas such as axillae and groin (<a href=\"image.htm?imageKey=DERM%2F59104%7EDERM%2F68137%7EDERM%2F53407\" class=\"graphic graphic_picture graphicRef59104 graphicRef68137 graphicRef53407 \">picture 11A-C</a>). Seborrheic dermatitis does not involve hands, feet, or nails, and there is no family history. Histology shows focal parakeratosis, psoriasiform acanthosis, and mild to moderate spongiosis; the complete absence of acantholytic dyskeratosis is a key criterion to differentiate seborrheic dermatitis from Darier disease. (See <a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults\" class=\"medical medical_review\">&quot;Seborrheic dermatitis in adolescents and adults&quot;</a>.) &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hailey-Hailey disease (familial benign pemphigus)</strong> &ndash; Hailey-Hailey disease (HHD) primarily affects the intertriginous areas and may be difficult to differentiate from Darier disease with flexural involvement (<a href=\"image.htm?imageKey=DERM%2F76004\" class=\"graphic graphic_picture graphicRef76004 \">picture 12</a>). Nail dystrophy is typically absent in HHD. Histology shows areas of partial suprabasal acantholysis with the characteristic appearance of a &quot;dilapidated brick wall&quot; (<a href=\"image.htm?imageKey=DERM%2F75555\" class=\"graphic graphic_picture graphicRef75555 \">picture 13</a>). (See <a href=\"topic.htm?path=hailey-hailey-disease-benign-familial-pemphigus\" class=\"medical medical_review\">&quot;Hailey-Hailey disease (benign familial pemphigus)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Grover disease (transient and persistent acantholytic dermatosis)</strong> &ndash; Grover disease is an uncommon pruritic, papular, or papulovesicular rash that most commonly affects the trunk, but the papules are not confluent as in Darier disease (<a href=\"image.htm?imageKey=PC%2F76504\" class=\"graphic graphic_picture graphicRef76504 \">picture 14</a>). The face, oral cavity, palms, soles, or nails are not involved, and there is no family history. Histology shows subtle and focal acantholysis, with intraepidermal clefts and dyskeratotic cells (<a href=\"image.htm?imageKey=PC%2F56584\" class=\"graphic graphic_picture graphicRef56584 \">picture 15</a>). (See <a href=\"topic.htm?path=grovers-disease-transient-and-persistent-acantholytic-dermatosis\" class=\"medical medical_review\">&quot;Grover's disease (transient and persistent acantholytic dermatosis)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7872169\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no cure for Darier disease. The goals of treatment are the improvement of the skin appearance, relief of symptoms (eg, irritation, pruritus, or malodor), and prevention or treatment of infectious complications. </p><p class=\"headingAnchor\" id=\"H52210573\"><span class=\"h2\">General measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients with Darier disease should be educated about simple measures to reduce the impact of exacerbating factors and control skin irritation. These measures include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Keeping the skin cool and minimizing perspiration. Flares may be prevented by wearing lightweight cotton clothes, avoiding hot environments, and using sunscreens, especially during the summer. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Regular use of moisturizers containing keratolytics such as topical urea or lactic acid. Moisturizers reduce irritation, decrease scaling and hyperkeratosis, and improve the skin appearance. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of antiseptic washes containing triclosan or <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> gluconate or bleach baths (one-fourth cup [60 mL] of household bleach in a full tub of water). Antiseptics reduce the burden of skin bacteria and odor. Patients may also be instructed to soak in astringents, such as <a href=\"topic.htm?path=aluminum-acetate-drug-information\" class=\"drug drug_general\">aluminum acetate</a>, if crusting is prominent or bacterial overgrowth is suspected. </p><p/><p class=\"headingAnchor\" id=\"H52210643\"><span class=\"h2\">Topical treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical therapies for Darier disease are aimed at controlling skin inflammation, reducing hyperkeratosis, and flattening the papular lesions. Topical treatments include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical corticosteroids</strong> &ndash; Low- to medium-potency topical corticosteroids (groups 4 to 6 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) may reduce skin inflammation. Although their efficacy has not been evaluated in clinical trials, they are frequently used in patients with Darier disease on the basis of their anti-inflammatory properties and clinical experience. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical retinoids</strong> &ndash; Topical retinoids, including tretinoin 0.1% [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/63\" class=\"abstract_t\">63</a>], <a href=\"topic.htm?path=adapalene-drug-information\" class=\"drug drug_general\">adapalene</a> 0.1% [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/64\" class=\"abstract_t\">64</a>], and <a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">tazarotene</a> 0.05% [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/65\" class=\"abstract_t\">65</a>], have been used in patients with mild or localized disease to reduce hyperkeratosis and flatten papular lesions. As monotherapy, their efficacy has not been evaluated in clinical trials.<strong> </strong>Based upon clinical experience, topical retinoids are preferred to other topical agents, such as topical vitamin D analogues. Irritation is common and can be reduced by alternate-day application and liberal use of emollients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other topical agents </strong>&ndash; There are isolated reports of response to treatment with topical 5-fluorouracil, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/66\" class=\"abstract_t\">66</a>], <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a> [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/67\" class=\"abstract_t\">67</a>], tacalcitol [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/68\" class=\"abstract_t\">68</a>], and <a href=\"topic.htm?path=diclofenac-drug-information\" class=\"drug drug_general\">diclofenac</a> sodium 3% gel [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/69\" class=\"abstract_t\">69</a>]. </p><p/><p class=\"headingAnchor\" id=\"H52210686\"><span class=\"h2\">Systemic treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral retinoids, including <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a>, <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, etretinate, and <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">alitretinoin</a>, decrease hyperkeratosis, smoothen papules, reduce odor, and produce significant clinical improvements in most patients with severe or generalized Darier disease. Etretinate is no longer available and has been replaced by acitretin. </p><p><a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">Acitretin</a> and <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> are usually given at a dose of up to 0.5 and 1 <span class=\"nowrap\">mg/kg</span> per day, respectively. Oral <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">alitretinoin</a> (available in Europe and Canada, but not in the United States) is used at doses of 10 or 30 mg per day. (See <a href=\"#H17980233\" class=\"local\">'Patients with severe or generalized disease'</a> below.)</p><p>The efficacy of oral retinoids for the treatment of Darier disease has not been evaluated in randomized trials, and evidence is limited to small observational studies [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/70-72\" class=\"abstract_t\">70-72</a>]. In a double-blind study including 26 patients with Darier disease treated with 30 mg per day of <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> or etretinate for four months, remission or marked improvement was achieved in 18 of 24 patients who took the drug for the duration of the study period, without difference between the two drugs [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/72\" class=\"abstract_t\">72</a>]. <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">Alitretinoin</a>, a vitamin A analogue known to have anti-inflammatory and immunomodulating properties, has been successfully used in a few patients [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/73,74\" class=\"abstract_t\">73,74</a>] but may induce considerable adverse effects, including worsening of the skin lesions, pyogenic granuloma, erosions, and fever [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/75\" class=\"abstract_t\">75</a>].</p><p>Oral retinoids do not induce prolonged remission in Darier disease, and long-term treatment is needed to prevent relapse. Adverse effects of systemic retinoids include mucosal dryness, headache, delayed dark adaptation, diffuse hair loss (telogen effluvium), pyogenic granuloma, photosensitivity, hyperlipidemia, transaminase elevation, and skeletal hyperostosis. Oral retinoids are teratogenic, and appropriate counseling and contraception must be given to women of childbearing age. </p><p class=\"headingAnchor\" id=\"H52210715\"><span class=\"h2\">Surgical or destructive therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approaches for localized hypertrophic, erosive, or recalcitrant lesions that are resistant to conventional treatment include dermabrasion, electrosurgery, laser ablation, surgical excision, and photodynamic therapy [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/76-86\" class=\"abstract_t\">76-86</a>]. None of these treatments has been evaluated in clinical trials. However, they may be beneficial in some patients. Recurrence of lesions following excision is common.</p><p class=\"headingAnchor\" id=\"H58288203\"><span class=\"h2\">Treatment of complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intermittent use of topical agents is helpful in treating malodor due to microbial colonization and mild secondary infections. Such bacterial or fungal superinfections are generally treated with topical antibiotics or antifungals (eg, <a href=\"topic.htm?path=mupirocin-drug-information\" class=\"drug drug_general\">mupirocin</a> 2% cream, <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> 0.1% cream, <a href=\"topic.htm?path=fusidic-acid-united-states-not-available-drug-information\" class=\"drug drug_general\">fusidic acid</a> 2% cream, or <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% cream). Antibacterial washes such as <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> gluconate&nbsp;4% wash may be used as an adjunct to topical antibiotics. Patients with extensive cutaneous infection that does not respond to topical treatment may require systemic treatment with oral antibiotics or antifungals guided by culture results. </p><p>Patients with eczema herpeticum are treated with oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> or <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>. (See <a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients#H20\" class=\"medical medical_review\">&quot;Treatment of herpes simplex virus type 1 infection in immunocompetent patients&quot;, section on 'Atopic eczema, burns, and other skin disorders'</a>.)</p><p class=\"headingAnchor\" id=\"H17980217\"><span class=\"h1\">APPROACH TO MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patient education about avoidance of triggers (eg, heat, sun exposure, sweating, or friction), control of skin irritation, and prevention of superinfection is an important component of treatment. The choice of topical or systemic therapies is based upon the disease severity and patient's preference. Since Darier disease is an autosomal dominant disorder with high penetrance, genetic counseling should be offered if appropriate. </p><p class=\"headingAnchor\" id=\"H17980225\"><span class=\"h2\">Patients with mild or localized disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with mild or localized disease, avoidance of triggers, regular use of emollients, and intermittent use of medium-potency topical corticosteroids (groups 4 and 5 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)), often combined with antibiotics (eg, <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>, <a href=\"topic.htm?path=fusidic-acid-united-states-not-available-drug-information\" class=\"drug drug_general\">fusidic acid</a>), are generally sufficient to control symptoms. (See <a href=\"#H52210573\" class=\"local\">'General measures'</a> above.) </p><p>For patients with mild or localized disease that is not controlled by emollients and topical corticosteroids, we suggest topical retinoids. Tretinoin 0.05% or 0.1% cream, <a href=\"topic.htm?path=adapalene-drug-information\" class=\"drug drug_general\">adapalene</a> 0.1% cream, or <a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">tazarotene</a> 0.05% or 0.1% cream are applied to the involved skin once daily for three months. </p><p>Because of the irritancy potential of topical retinoids, treatment is started with the lowest retinoid concentration applied on alternate days. After the first two weeks of treatment, frequency of application and retinoid concentration are gradually increased as tolerated. Emollients are used liberally in conjunction with topical retinoids. Intermittent use of medium-potency topical corticosteroids (groups 4 and 5 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) may reduce retinoid-induced irritation.</p><p>Treatment with topical retinoids should not be started during pregnancy and should be discontinued in patients who become pregnant, although there is no direct evidence that topical retinoids cause congenital malformations [<a href=\"https://www.uptodate.com/contents/darier-disease/abstract/87,88\" class=\"abstract_t\">87,88</a>].</p><p class=\"headingAnchor\" id=\"H17980233\"><span class=\"h2\">Patients with severe or generalized disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest oral retinoids such as <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> or <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> for patients with severe or extensive Darier disease. Treatment is generally started with a low dose (10 to 25 mg per day) to avoid initial exacerbation of the disease; the dose is then gradually increased as tolerated, up to 0.5 <span class=\"nowrap\">mg/kg</span> per day for acitretin and 1 <span class=\"nowrap\">mg/kg</span> per day for isotretinoin. <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">Alitretinoin</a> is started at a dose of 10 mg per day and may be increased to 30 mg per day. Treatment should be continued for a minimum of three to four months to achieve reduction of hyperkeratosis, flattening of papular lesions, and reduction of malodor. Long-term treatment is needed to prevent relapse.</p><p>Common side effects of systemic retinoids include mucosal and skin dryness, cheilitis, headache, delayed dark adaptation, diffuse hair loss, pyogenic granuloma, photosensitivity, hyperlipidemia, and elevation of liver transaminase levels. Long-term use induces skeletal hyperostosis on ligaments. Measurement of baseline serum lipid and liver enzyme levels is indicated before initiating <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> or <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy. Monitoring of serum lipid and liver enzyme levels for the first two months and then every three months is adequate for patients on long-term retinoid therapy. </p><p><a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">Acitretin</a>, <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">alitretinoin</a>,&nbsp;and <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> are teratogenic. Appropriate counseling and contraception must be given to women of childbearing age before starting oral retinoids. Women should avoid pregnancy for <strong>three years</strong>&nbsp;after discontinuing acitretin and for <strong>one month</strong> after discontinuation of isotretinoin or alitretinoin. Isotretinoin or alitretinoin are thus preferred to acitretin for women of childbearing age who have severe Darier disease. Oral retinoids should never be combined with systemic <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> or tetracyclines. (See <a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris#H7\" class=\"medical medical_review\">&quot;Oral isotretinoin therapy for acne vulgaris&quot;, section on 'Isotretinoin safety'</a>.)</p><p>For patients with localized hypertrophic lesions that do not respond to oral retinoids, surgical excision, laser ablation, or photodynamic therapy are therapeutic options. However, these approaches are associated with pain <span class=\"nowrap\">and/or</span> scarring, and their long-term benefits are uncertain. (See <a href=\"#H52210715\" class=\"local\">'Surgical or destructive therapies'</a> above.)</p><p class=\"headingAnchor\" id=\"H7872176\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with Darier disease have a normal life expectancy, although their quality of life may be significantly impaired. The disease follows a chronic course, and relapse is common when treatment is stopped.</p><p class=\"headingAnchor\" id=\"H58288266\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Darier disease, also known as Darier-White disease, keratosis, or dyskeratosis follicularis (MIM #1242000), is a rare autosomal dominant genodermatosis characterized by a persistent eruption of greasy, hyperkeratotic papules in seborrheic regions, nail abnormalities, and mucosal changes. Sporadic cases due to de novo mutations are common. (See <a href=\"#H7872118\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Darier disease is caused by mutations in the <em>ATP2A2</em> gene on 12q23-24.1 that encodes a <span class=\"nowrap\">sarcoplasmic/endoplasmic</span> reticulum calcium pump (SERCA2). Acantholysis and dyskeratosis are the histologic hallmark of Darier disease (<a href=\"image.htm?imageKey=DERM%2F86189\" class=\"graphic graphic_picture graphicRef86189 \">picture 1</a>). (See <a href=\"#H7872132\" class=\"local\">'Pathogenesis'</a> above and <a href=\"#H49418038\" class=\"local\">'Histopathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial lesions of Darier disease appear during the teenage years as skin-colored or yellow-brown, keratotic papules that involve the face, chest, back, and, less frequently, the flexural areas (<a href=\"image.htm?imageKey=DERM%2F70000%7EDERM%2F56168%7EDERM%2F86186%7EDERM%2F86187%7EDERM%2F86188\" class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188 \">picture 2A-E</a>). Nail changes, including red and white longitudinal bands with a V-shaped nick at the free margin of the nail, are frequent and characteristic (<a href=\"image.htm?imageKey=DERM%2F81865\" class=\"graphic graphic_picture graphicRef81865 \">picture 7</a>). (See <a href=\"#H7872139\" class=\"local\">'Clinical features'</a> above and <a href=\"#H58289039\" class=\"local\">'Clinical variants'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of Darier disease is suggested by the clinical finding of a persistent eruption of keratotic papules involving the seborrheic areas. A skin biopsy for<strong> </strong>histologic examination is needed to confirm the diagnosis and exclude other conditions with similar clinical findings. (See <a href=\"#H7872153\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H7872160\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with mild or localized disease, avoidance of triggers, regular use of emollients, and intermittent use of medium-potency topical corticosteroids (groups 4 and 5 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) are generally sufficient to control symptoms. For patients with limited disease that is not controlled by emollients, we suggest topical retinoids such as tretinoin 0.05% cream, <a href=\"topic.htm?path=adapalene-drug-information\" class=\"drug drug_general\">adapalene</a> 0.1% cream, or <a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">tazarotene</a> 0.05% cream (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Topical retinoids are applied once a day for three months. (See <a href=\"#H52210573\" class=\"local\">'General measures'</a> above and <a href=\"#H17980225\" class=\"local\">'Patients with mild or localized disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest oral retinoids such as <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a>, <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, or <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">alitretinoin</a> for patients with severe or extensive Darier disease (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Acitretin or isotretinoin is given at a dose of 0.5 <span class=\"nowrap\">mg/kg</span> per day for three to four months and alitretinoin at 10 or 30 mg per day. For women of childbearing age, isotretinoin is preferred to acitretin. (See <a href=\"#H17980233\" class=\"local\">'Patients with severe or generalized disease'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1310525708\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Pui-Yan Kwok, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/1\" class=\"nounderline abstract_t\">Darier FJ. De la psorospermose folliculaire v&eacute;g&eacute;tante. Annales de dermatologie et de syphilographie 1889; 10:597.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/2\" class=\"nounderline abstract_t\">Cooper SM, Burge SM. Darier's disease: epidemiology, pathophysiology, and management. Am J Clin Dermatol 2003; 4:97.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/3\" class=\"nounderline abstract_t\">Godic A, Miljkovic J, Kansky A, Vidmar G. Epidemiology of Darier's Disease in Slovenia. Acta Dermatovenerol Alp Pannonica Adriat 2005; 14:43.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/4\" class=\"nounderline abstract_t\">Sakuntabhai A, Ruiz-Perez V, Carter S, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 1999; 21:271.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/5\" class=\"nounderline abstract_t\">Miyauchi Y, Daiho T, Yamasaki K, et al. Comprehensive analysis of expression and function of 51 sarco(endo)plasmic reticulum Ca2+-ATPase mutants associated with Darier disease. J Biol Chem 2006; 281:22882.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/6\" class=\"nounderline abstract_t\">Dhitavat J, Fairclough RJ, Hovnanian A, Burge SM. Calcium pumps and keratinocytes: lessons from Darier's disease and Hailey-Hailey disease. Br J Dermatol 2004; 150:821.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/7\" class=\"nounderline abstract_t\">Dhitavat J, Cobbold C, Leslie N, et al. Impaired trafficking of the desmoplakins in cultured Darier's disease keratinocytes. J Invest Dermatol 2003; 121:1349.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/8\" class=\"nounderline abstract_t\">Leinonen PT, H&auml;gg PM, Peltonen S, et al. Reevaluation of the normal epidermal calcium gradient, and analysis of calcium levels and ATP receptors in Hailey-Hailey and Darier epidermis. J Invest Dermatol 2009; 129:1379.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/9\" class=\"nounderline abstract_t\">Savignac M, Simon M, Edir A, et al. SERCA2 dysfunction in Darier disease causes endoplasmic reticulum stress and impaired cell-to-cell adhesion strength: rescue by Miglustat. J Invest Dermatol 2014; 134:1961.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/10\" class=\"nounderline abstract_t\">Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009; 1:268.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/11\" class=\"nounderline abstract_t\">Wang Y, Bruce AT, Tu C, et al. Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes. J Cell Sci 2011; 124:3568.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/12\" class=\"nounderline abstract_t\">Foggia L, Aronchik I, Aberg K, et al. Activity of the hSPCA1 Golgi Ca2+ pump is essential for Ca2+-mediated Ca2+ response and cell viability in Darier disease. J Cell Sci 2006; 119:671.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/13\" class=\"nounderline abstract_t\">Savignac M, Edir A, Simon M, Hovnanian A. Darier disease : a disease model of impaired calcium homeostasis in the skin. Biochim Biophys Acta 2011; 1813:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/14\" class=\"nounderline abstract_t\">Celli A, Mackenzie DS, Zhai Y, et al. SERCA2-controlled Ca&sup2;+-dependent keratinocyte adhesion and differentiation is mediated via the sphingolipid pathway: a therapeutic target for Darier's disease. J Invest Dermatol 2012; 132:1188.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/15\" class=\"nounderline abstract_t\">Hobbs RP, Amargo EV, Somasundaram A, et al. The calcium ATPase SERCA2 regulates desmoplakin dynamics and intercellular adhesive strength through modulation of PKC&amp;alpha; signaling. FASEB J 2011; 25:990.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/16\" class=\"nounderline abstract_t\">Green EK, Gordon-Smith K, Burge SM, et al. Novel ATP2A2 mutations in a large sample of individuals with Darier disease. J Dermatol 2013; 40:259.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/17\" class=\"nounderline abstract_t\">Nellen RG, Steijlen PM, van Steensel MA, et al. Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease. Hum Mutat 2017; 38:343.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/18\" class=\"nounderline abstract_t\">Bchetnia M, Charfeddine C, Kassar S, et al. Clinical and mutational heterogeneity of Darier disease in Tunisian families. Arch Dermatol 2009; 145:654.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/19\" class=\"nounderline abstract_t\">Dhitavat J, Macfarlane S, Dode L, et al. Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2: evidence that it is allelic to Darier's disease. J Invest Dermatol 2003; 120:229.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/20\" class=\"nounderline abstract_t\">Bergman R, Sezin T, Indelman M, et al. Acrokeratosis verruciformis of Hopf showing P602L mutation in ATP2A2 and overlapping histopathological features with Darier disease. Am J Dermatopathol 2012; 34:597.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/21\" class=\"nounderline abstract_t\">Berk DR, Taube JM, Bruckner AL, Lane AT. A sporadic patient with acrokeratosis verruciformis of Hopf and a novel ATP2A2 mutation. Br J Dermatol 2010; 163:653.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/22\" class=\"nounderline abstract_t\">Ruiz-Perez VL, Carter SA, Healy E, et al. ATP2A2 mutations in Darier's disease: variant cutaneous phenotypes are associated with missense mutations, but neuropsychiatric features are independent of mutation class. Hum Mol Genet 1999; 8:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/23\" class=\"nounderline abstract_t\">Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 1992; 27:40.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/24\" class=\"nounderline abstract_t\">Munro CS. The phenotype of Darier's disease: penetrance and expressivity in adults and children. Br J Dermatol 1992; 127:126.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/25\" class=\"nounderline abstract_t\">Burge S. Darier's disease--the clinical features and pathogenesis. Clin Exp Dermatol 1994; 19:193.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/26\" class=\"nounderline abstract_t\">Macleod RI, Munro CS. The incidence and distribution of oral lesions in patients with Darier's disease. Br Dent J 1991; 171:133.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/27\" class=\"nounderline abstract_t\">Su&aacute;rez-Pe&ntilde;aranda JM, Ant&uacute;nez JR, Del Rio E, et al. Vaginal involvement in a woman with Darier's disease: a case report. Acta Cytol 2005; 49:530.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/28\" class=\"nounderline abstract_t\">Vieites B, Seijo-R&iacute;os S, Su&aacute;rez-Pe&ntilde;aranda JM, et al. Darier's disease with esophageal involvement. Scand J Gastroenterol 2008; 43:1020.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/29\" class=\"nounderline abstract_t\">Salopek TG, Krol A, Jimbow K. Case report of Darier disease localized to the vulva in a 5-year-old girl. Pediatr Dermatol 1993; 10:146.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/30\" class=\"nounderline abstract_t\">Bernab&eacute; DG, Kawata LT, Beneti IM, et al. Multiple white papules in the palate: oral manifestation of Darier's disease. Clin Exp Dermatol 2009; 34:e270.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/31\" class=\"nounderline abstract_t\">Gordon-Smith K, Jones LA, Burge SM, et al. The neuropsychiatric phenotype in Darier disease. Br J Dermatol 2010; 163:515.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/32\" class=\"nounderline abstract_t\">Dodiuk-Gad R, Lerner M, Breznitz Z, et al. Learning disabilities in Darier's disease patients. J Eur Acad Dermatol Venereol 2014; 28:314.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/33\" class=\"nounderline abstract_t\">Jacobsen NJ, Lyons I, Hoogendoorn B, et al. ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes. Hum Mol Genet 1999; 8:1631.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/34\" class=\"nounderline abstract_t\">Green E, Elvidge G, Jacobsen N, et al. Localization of bipolar susceptibility locus by molecular genetic analysis of the chromosome 12q23-q24 region in two pedigrees with bipolar disorder and Darier's disease. Am J Psychiatry 2005; 162:35.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/35\" class=\"nounderline abstract_t\">Cederl&ouml;f M, Bergen SE, L&aring;ngstr&ouml;m N, et al. The association between Darier disease, bipolar disorder, and schizophrenia revisited: a population-based family study. Bipolar Disord 2015; 17:340.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/36\" class=\"nounderline abstract_t\">Cederl&ouml;f M, Karlsson R, Larsson H, et al. Intellectual disability and cognitive ability in Darier disease: Swedish nation-wide study. Br J Dermatol 2015; 173:155.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/37\" class=\"nounderline abstract_t\">Nakamura T, Kazuno AA, Nakajima K, et al. Loss of function mutations in ATP2A2 and psychoses: A case report and literature survey. Psychiatry Clin Neurosci 2016; 70:342.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/38\" class=\"nounderline abstract_t\">Telfer NR, Burge SM, Ryan TJ. Vesiculo-bullous Darier's disease. Br J Dermatol 1990; 122:831.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/39\" class=\"nounderline abstract_t\">Rongioletti F, Cestari R, Rebora A. Verrucous and malodorous vegetations on the legs. Darier's disease, cornifying type. Arch Dermatol 1992; 128:399, 402.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/40\" class=\"nounderline abstract_t\">Foresman PL, Goldsmith LA, Ginn L, Beck AL. Hemorrhagic Darier's disease. Arch Dermatol 1993; 129:511.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/41\" class=\"nounderline abstract_t\">JONES WN, NIX TE Jr, CLARK WH Jr. HEMORRHAGIC DARIER'S DISEASE. Arch Dermatol 1964; 89:523.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/42\" class=\"nounderline abstract_t\">Meziane M, Chraibi R, Kihel N, et al. Linear Darier disease. Dermatol Online J 2008; 14:11.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/43\" class=\"nounderline abstract_t\">Sakuntabhai A, Dhitavat J, Burge S, Hovnanian A. Mosaicism for ATP2A2 mutations causes segmental Darier's disease. J Invest Dermatol 2000; 115:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/44\" class=\"nounderline abstract_t\">F&ouml;lster-Holst R, Nellen RG, Jensen JM, et al. Molecular genetic support for the rule of dichotomy in type 2 segmental Darier disease. Br J Dermatol 2012; 166:464.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/45\" class=\"nounderline abstract_t\">Flores-Terry M&Aacute;, Garc&iacute;a-Arpa M, Llamas-Velasco M, et al. Acral Hemorrhagic Darier Disease. Actas Dermosifiliogr 2017; 108:e49.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/46\" class=\"nounderline abstract_t\">Vender R, Vender R. Acral Hemorrhagic Darier's Disease: A Case Report. J Cutan Med Surg 2016; 20:478.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/47\" class=\"nounderline abstract_t\">J&ouml;rg B, Erhard H, R&uuml;tten A. [A hemorrhagic acral form of dyskeratosis follicularis Darier]. Hautarzt 2000; 51:857.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/48\" class=\"nounderline abstract_t\">Ronan A, Ingrey A, Murray N, Chee P. Recurrent ATP2A2 p.(Pro602Leu) mutation differentiates Acrokeratosis verruciformis of Hopf from the allelic condition Darier disease. Am J Med Genet A 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/49\" class=\"nounderline abstract_t\">Harman M, Durdu M, &#304;bilo&#287;lu I. Acrokeratosis verruciformis of Hopf exhibiting Darier disease-like cytological features. Clin Exp Dermatol 2016; 41:761.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/50\" class=\"nounderline abstract_t\">Mayuzumi N, Ikeda S, Kawada H, et al. Effects of ultraviolet B irradiation, proinflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1. Br J Dermatol 2005; 152:697.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/51\" class=\"nounderline abstract_t\">Ehrt U, Brieger P. Comorbidity of keratosis follicularis (Darier's Disease) and bipolar affective disorder: an indication for valproate instead of lithium. Gen Hosp Psychiatry 2000; 22:128.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/52\" class=\"nounderline abstract_t\">Nath AK, Udayashankar C. Diltiazem worsens Darier's disease. Int J Dermatol 2014; 53:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/53\" class=\"nounderline abstract_t\">Okada E, Nagai Y, Motegi S, et al. Fatal case of Darier's disease with recurrent severe infections. Acta Derm Venereol 2009; 89:408.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/54\" class=\"nounderline abstract_t\">Woo SM, Won CH, Cho S. Darier's disease: variable clinical presentation and a fatal outcome. Clin Exp Dermatol 2009; 34:628.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/55\" class=\"nounderline abstract_t\">Haase O, Moser A, Rose C, et al. Generalized cowpox infection in a patient with Darier disease. Br J Dermatol 2011; 164:1116.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/56\" class=\"nounderline abstract_t\">Vogt KA, Lohse CM, El-Azhary RA, et al. Kaposi varicelliform eruption in patients with Darier disease: a 20-year retrospective study. J Am Acad Dermatol 2015; 72:481.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/57\" class=\"nounderline abstract_t\">Czyz C, Sharma P, Grossniklaus HE, et al. Clinical and pathologic eyelid alterations in a patient with Darier disease. Ophthal Plast Reconstr Surg 2011; 27:e170.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/58\" class=\"nounderline abstract_t\">Carlsson AM, Barrett GD. Postoperative endophthalmitis in a patient with Darier-White disease. Can J Ophthalmol 2007; 42:134.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/59\" class=\"nounderline abstract_t\">Mielke J, Gr&uuml;b M, Besch D, Schlote T. Recurrent corneal ulcerations with perforation in keratosis follicularis (Darier-White disease). Br J Ophthalmol 2002; 86:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/60\" class=\"nounderline abstract_t\">Radia M, Gilhooley MJ, Panos C, Claou&eacute; C. Recurrent presumed herpes simplex keratitis and episcleritis in keratosis follicularis (Darier's disease). BMJ Case Rep 2015; 2015.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/61\" class=\"nounderline abstract_t\">Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol 2008; 159:137.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/62\" class=\"nounderline abstract_t\">Matsui K, Makino T, Nakano H, et al. Squamous cell carcinoma arising from Darier's disease. Clin Exp Dermatol 2009; 34:e1015.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/63\" class=\"nounderline abstract_t\">Dogan S, Karaduman A, Erkin G, Gokoz O. Effective treatment of linear Darier's disease with topical retinoids: case report and review of the literature. Acta Dermatovenerol Croat 2011; 19:206.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/64\" class=\"nounderline abstract_t\">Casals M, Campoy A, Aspiolea F, et al. Successful treatment of linear Darier's disease with topical adapalene. J Eur Acad Dermatol Venereol 2009; 23:237.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/65\" class=\"nounderline abstract_t\">Burkhart CG, Burkhart CN. Tazarotene gel for Darier's disease. J Am Acad Dermatol 1998; 38:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/66\" class=\"nounderline abstract_t\">Rubegni P, Poggiali S, Sbano P, et al. A case of Darier's disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol 2006; 20:84.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/67\" class=\"nounderline abstract_t\">P&eacute;rez-Carmona L, Fleta-As&iacute;n B, Moreno-Garc&iacute;a-Del-Real C, Ja&eacute;n-Olasolo P. Successful treatment of Darier's disease with topical pimecrolimus. Eur J Dermatol 2011; 21:301.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/68\" class=\"nounderline abstract_t\">Abe M, Yasuda M, Yokoyama Y, Ishikawa O. Successful treatment of combination therapy with tacalcitol lotion associated with sunscreen for localized Darier's disease. J Dermatol 2010; 37:718.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/69\" class=\"nounderline abstract_t\">Mill&aacute;n-Parrilla F, Rodrigo-Nicol&aacute;s B, Mol&eacute;s-Poveda P, et al. Improvement of Darier disease with diclofenac sodium 3% gel. J Am Acad Dermatol 2014; 70:e89.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/70\" class=\"nounderline abstract_t\">Farb RM, Lazarus GS, Chiaramonti A, et al. The effect of 13-cis retinoic acid on epidermal lysosomal hydrolase activity in Darier's disease and pityriasis rubra pilaris. J Invest Dermatol 1980; 75:133.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/71\" class=\"nounderline abstract_t\">Suzuki K, Aoki M, Kawana S. Localized Darier's disease of the scalp: successful treatment with oral etretinate. Dermatology 2004; 208:83.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/72\" class=\"nounderline abstract_t\">Christophersen J, Geiger JM, Danneskiold-Samsoe P, et al. A double-blind comparison of acitretin and etretinate in the treatment of Darier's disease. Acta Derm Venereol 1992; 72:150.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/73\" class=\"nounderline abstract_t\">Letul&eacute; V, Herzinger T, Ruzicka T, Molin S. Treatment of Darier disease with oral alitretinoin. Clin Exp Dermatol 2013; 38:523.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/74\" class=\"nounderline abstract_t\">Anuset D, Goutorbe C, Bernard P, Reguiai Z. Efficacy of oral alitretinoin for the treatment of Darier disease: a case report. J Am Acad Dermatol 2014; 71:e46.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/75\" class=\"nounderline abstract_t\">Balestri R, Patrizi A, Bardazzi F. Alitretinoin and Darier disease: &quot;All that glisters is not gold&quot;. J Am Acad Dermatol 2015; 72:363.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/76\" class=\"nounderline abstract_t\">Wheeland RG, Gilmore WA. The surgical treatment of hypertrophic Darier's disease. J Dermatol Surg Oncol 1985; 11:420.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/77\" class=\"nounderline abstract_t\">Toombs EL, Peck GL. Electrosurgical treatment of etretinate-resistant Darier's disease. J Dermatol Surg Oncol 1989; 15:1277.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/78\" class=\"nounderline abstract_t\">Ahcan U, Dolenc-Voljc M, Zivec K, et al. The surgical treatment of hypertrophic intertriginous Darier's disease. J Plast Reconstr Aesthet Surg 2009; 62:e442.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/79\" class=\"nounderline abstract_t\">Brown VL, Kelly SE, Burge SM, Walker NP. Extensive recalcitrant Darier disease successfully treated with laser ablation. Br J Dermatol 2010; 162:227.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/80\" class=\"nounderline abstract_t\">McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease. J Am Acad Dermatol 1990; 23:893.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/81\" class=\"nounderline abstract_t\">Minsue Chen T, Wanitphakdeedecha R, Nguyen TH. Carbon dioxide laser ablation and adjunctive destruction for Darier-White disease (keratosis follicularis). Dermatol Surg 2008; 34:1431.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/82\" class=\"nounderline abstract_t\">Beier C, Kaufmann R. Efficacy of erbium:YAG laser ablation in Darier disease and Hailey-Hailey disease. Arch Dermatol 1999; 135:423.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/83\" class=\"nounderline abstract_t\">Roos S, Karsai S, Ockenfel HM, Raulin C. Successful treatment of Darier disease with the flashlamp-pumped pulsed-dye laser. Arch Dermatol 2008; 144:1073.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/84\" class=\"nounderline abstract_t\">Katz TM, Firoz BF, Goldberg LH, Friedman PM. Treatment of Darier's disease using a 1,550-nm erbium-doped fiber laser. Dermatol Surg 2010; 36:142.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/85\" class=\"nounderline abstract_t\">Exadaktylou D, Kurwa HA, Calonje E, Barlow RJ. Treatment of Darier's disease with photodynamic therapy. Br J Dermatol 2003; 149:606.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/86\" class=\"nounderline abstract_t\">Avery HL, Hughes BR, Coley C, Cooper HL. Clinical improvement in Darier's disease with photodynamic therapy. Australas J Dermatol 2010; 51:32.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/87\" class=\"nounderline abstract_t\">Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005; 136:117.</a></li><li><a href=\"https://www.uptodate.com/contents/darier-disease/abstract/88\" class=\"nounderline abstract_t\">Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet 1997; 350:1143.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15462 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H58288266\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H7872118\" id=\"outline-link-H7872118\">INTRODUCTION</a></li><li><a href=\"#H7872125\" id=\"outline-link-H7872125\">EPIDEMIOLOGY</a></li><li><a href=\"#H7872132\" id=\"outline-link-H7872132\">PATHOGENESIS</a></li><li><a href=\"#H31790782\" id=\"outline-link-H31790782\">GENETICS</a></li><li><a href=\"#H49418038\" id=\"outline-link-H49418038\">HISTOPATHOLOGY</a></li><li><a href=\"#H7872139\" id=\"outline-link-H7872139\">CLINICAL FEATURES</a><ul><li><a href=\"#H49417901\" id=\"outline-link-H49417901\">Skin lesions</a></li><li><a href=\"#H49417908\" id=\"outline-link-H49417908\">Nail changes</a></li><li><a href=\"#H49417918\" id=\"outline-link-H49417918\">Mucosal lesions</a></li><li><a href=\"#H58289047\" id=\"outline-link-H58289047\">Symptoms</a></li><li><a href=\"#H49417925\" id=\"outline-link-H49417925\">Associated neuropsychiatric abnormalities</a></li></ul></li><li><a href=\"#H58289039\" id=\"outline-link-H58289039\">CLINICAL VARIANTS</a><ul><li><a href=\"#H96302336\" id=\"outline-link-H96302336\">Segmental variant</a></li><li><a href=\"#H161132089\" id=\"outline-link-H161132089\">Acral hemorrhagic variant</a></li><li><a href=\"#H1908421141\" id=\"outline-link-H1908421141\">Acrokeratosis verruciformis of Hopf</a></li></ul></li><li><a href=\"#H49418100\" id=\"outline-link-H49418100\">CLINICAL COURSE AND COMPLICATIONS</a></li><li><a href=\"#H7872153\" id=\"outline-link-H7872153\">DIAGNOSIS</a></li><li><a href=\"#H7872160\" id=\"outline-link-H7872160\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H7872169\" id=\"outline-link-H7872169\">TREATMENT</a><ul><li><a href=\"#H52210573\" id=\"outline-link-H52210573\">General measures</a></li><li><a href=\"#H52210643\" id=\"outline-link-H52210643\">Topical treatment</a></li><li><a href=\"#H52210686\" id=\"outline-link-H52210686\">Systemic treatment</a></li><li><a href=\"#H52210715\" id=\"outline-link-H52210715\">Surgical or destructive therapies</a></li><li><a href=\"#H58288203\" id=\"outline-link-H58288203\">Treatment of complications</a></li></ul></li><li><a href=\"#H17980217\" id=\"outline-link-H17980217\">APPROACH TO MANAGEMENT</a><ul><li><a href=\"#H17980225\" id=\"outline-link-H17980225\">Patients with mild or localized disease</a></li><li><a href=\"#H17980233\" id=\"outline-link-H17980233\">Patients with severe or generalized disease</a></li></ul></li><li><a href=\"#H7872176\" id=\"outline-link-H7872176\">PROGNOSIS</a></li><li><a href=\"#H58288266\" id=\"outline-link-H58288266\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1310525708\" id=\"outline-link-H1310525708\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15462|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/86189\" class=\"graphic graphic_picture\">- Darier histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/70000\" class=\"graphic graphic_picture\">- Darier disease - dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/56168\" class=\"graphic graphic_picture\">- Darier disease - light skin</a></li><li><a href=\"image.htm?imageKey=DERM/86186\" class=\"graphic graphic_picture\">- Darier plaques</a></li><li><a href=\"image.htm?imageKey=DERM/86187\" class=\"graphic graphic_picture\">- Darier forehead</a></li><li><a href=\"image.htm?imageKey=DERM/86188\" class=\"graphic graphic_picture\">- Darier keratotic papule</a></li><li><a href=\"image.htm?imageKey=DERM/86185\" class=\"graphic graphic_picture\">- Darier plantar hyperkeratosis</a></li><li><a href=\"image.htm?imageKey=DERM/113564\" class=\"graphic graphic_picture\">- Darier nail white lines</a></li><li><a href=\"image.htm?imageKey=DERM/113565\" class=\"graphic graphic_picture\">- Darier nail red lines</a></li><li><a href=\"image.htm?imageKey=DERM/113566\" class=\"graphic graphic_picture\">- Darier nail notch</a></li><li><a href=\"image.htm?imageKey=DERM/81865\" class=\"graphic graphic_picture\">- Darier disease - nails</a></li><li><a href=\"image.htm?imageKey=DERM/86184\" class=\"graphic graphic_picture\">- Darier mucosal</a></li><li><a href=\"image.htm?imageKey=DERM/86092\" class=\"graphic graphic_picture\">- Acrokeratosis verruciformis</a></li><li><a href=\"image.htm?imageKey=DERM/86093\" class=\"graphic graphic_picture\">- Acrokeratosis verruciformis punctate keratoses</a></li><li><a href=\"image.htm?imageKey=DERM/113572\" class=\"graphic graphic_picture\">- Darier ocular</a></li><li><a href=\"image.htm?imageKey=DERM/59104\" class=\"graphic graphic_picture\">- Seborrheic dermatitis face 2</a></li><li><a href=\"image.htm?imageKey=DERM/68137\" class=\"graphic graphic_picture\">- Seborrheic dermatitis groin</a></li><li><a href=\"image.htm?imageKey=DERM/53407\" class=\"graphic graphic_picture\">- Seborrheic dermatitis axilla</a></li><li><a href=\"image.htm?imageKey=DERM/76004\" class=\"graphic graphic_picture\">- Hailey-Hailey 3</a></li><li><a href=\"image.htm?imageKey=DERM/75555\" class=\"graphic graphic_picture\">- Haley-Haley histology</a></li><li><a href=\"image.htm?imageKey=PC/76504\" class=\"graphic graphic_picture\">- Grover's disease</a></li><li><a href=\"image.htm?imageKey=PC/56584\" class=\"graphic graphic_picture\">- Grover's histology</a></li></ul></li><li><div id=\"DERM/15462|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of herpes simplex virus type 1 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gaucher-disease-treatment\" class=\"medical medical_review\">Gaucher disease: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=grovers-disease-transient-and-persistent-acantholytic-dermatosis\" class=\"medical medical_review\">Grover's disease (transient and persistent acantholytic dermatosis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hailey-hailey-disease-benign-familial-pemphigus\" class=\"medical medical_review\">Hailey-Hailey disease (benign familial pemphigus)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris\" class=\"medical medical_review\">Oral isotretinoin therapy for acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-niemann-pick-disease\" class=\"medical medical_review\">Overview of Niemann-Pick disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-nail-disorders\" class=\"medical medical_review\">Overview of nail disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults\" class=\"medical medical_review\">Seborrheic dermatitis in adolescents and adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients\" class=\"medical medical_review\">Treatment of herpes simplex virus type 1 infection in immunocompetent patients</a></li></ul></div></div>","javascript":null}